Our multidisciplinary team comprises specialists in various fields including cell culture, bioassays, pharmacology, biochemistry, systems biology, histopathology, omics, bioinformatics, and clinical oncology. Our initiative involves the establishment of Shansons PreciX, an innovative entity dedicated to crafting a precision medicine framework tailored for cancer treatment. Built upon our innovative theranostics technology, this initiative is supported by prominent scientific professionals in the fields of molecular biology and cancer research.
Its core function involves performing Chemoresponse tests on cancer patients utilizing biopsy samples. Leveraging advanced technologies like next-generation sequencing (NGS), the platform will scrutinize each patient's cancer genomic profile and cross-reference it with a repository of drug response data sourced from clinical trials and studies. Integrating artificial intelligence (AI), it will generate individualized treatment recommendations for the most effective chemotherapy and immunotherapy for each patient's cancer type.
Furthermore, the platform will facilitate the identification of new biomarkers, drug targets, and therapeutic approaches for combating cancer. Our objective is to establish a cutting-edge laboratory outfitted with state-of-the-art molecular analysis tools and drug discovery instrumentation to actualize this transformative platform.
Geographic Scope:
- American Continent:
- Includes North America (including the United States, Canada, and Mexico).
- Europe:
- Includes countries from Western Europe (e.g., Germany, France, United Kingdom) to Eastern Europe (e.g., Poland, Romania, Ukraine).
- Rich genetic diversity due to historical migrations and interactions.
- India:
- A vast and genetically diverse country with over 1.3 billion people.
- Unique genetic variations influenced by regional and ethnic factors.
Disease Focus:
- Cancer:
- Investigate precision medicine approaches for managing cancer.
- Inflammatory Bowel Disease (IBD):
- Investigate precision medicine approaches for managing IBD (Crohn’s disease, ulcerative colitis) in diverse populations.
- Rheumatoid Diseases:
- Explore personalized treatments for rheumatoid arthritis and related autoimmune conditions.
- Multiple Sclerosis (MS):
- Develop strategies to optimize MS management based on genetic and environmental factors.
Research and Data Collection:
- Collaborate with research institutions, hospitals, and clinics across continents.
- Collect genomic data, clinical records, lifestyle information, and environmental factors.
- Standardize data formats for interoperability.
AI-Driven Algorithms:
- Leverage artificial intelligence (AI) to analyze large datasets.
- Develop AI algorithms for disease prediction, drug response, and risk profiling.
Clinical Implementation:
- Implement precision medicine in clinical practice.
- Use companion diagnostics, pharmacogenomics, and targeted therapies.
- Optimize drug selection based on genetic variations.
Infrastructure and Interoperability:
- Establish a shared launchpad for medical AI algorithm development.
- Ensure data interoperability across continents.
- Bridge biomedical research and healthcare.
Patient-Centric Approach:
- Focus on patient outcomes and quality of life.
- Educate healthcare professionals about precision medicine.
- Address ethical, legal, and privacy considerations.
Collaboration and Funding:
- Foster collaboration among institutions, governments, and industry stakeholders.
- Seek funding from national research funds, private sector investments, and international partnerships.